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ABSTRACT: Electrophilic eicosanoids arise from the free radical-induced
peroxidation of arachidonic acid or its metabolites. These reactive species
may play an important role in pathophysiological processes associated
with inflammation and oxidative stress. Cyclopentenone prostaglandins
(cyPG) and isoprostanes are reactive eicosanoids that can form covalent
adducts with cysteine residues in proteins through Michael addition. In
pharmacological studies, cyPG have shown potent protective effects in
experimental models of inflammation and tissue injury, and they have
been proposed to contribute to inflammatory resolution. An important
mechanism for the anti-inflammatory effects of cyPG is the covalent
modification of critical cysteine residues in proteins involved in the mod-
ulation of inflammation, such as transcription factors NF-B and AP-1.
In recent years, analogs of electrophilic prostanoids have been used in
various approaches to identify biologically relevant protein targets for
this modification. Prostanoids with cyclopentenone structure have been
shown to target a defined subproteome that is beginning to be character-
ized. Structural studies suggest that diverse cyPG may modify distinct
proteins selectively. Functional studies put forward a dual role for these
compounds in the cellular response to inflammation or stress. There-
fore, a detailed knowledge of targets of electrophilic eicosanoids and the
functional consequences of their modification will contribute to the un-
derstanding of their mechanism of action and help assess whether these
endogenous mediators can be exploited as the basis for the development
of novel therapeutic strategies. In this article we discuss the recent ad-
vances in this rapidly growing field.
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INTRODUCTION
The formation of reactive species in living cells is a process cosubstantial
with normal cell activity and it can be increased under pathophysiological con-
ditions. These reactive intermediates are required for normal cell metabolism
and gene expression and constitute important players in cell signaling. How-
ever, they can also damage cellular components, like DNA and proteins.1
Reactive intermediates can be derived from the use of oxygen by living cells,
like superoxide anion or hydrogen peroxide, nitric oxide (NO), and peroxyni-
trite. These species can act through a wide array of mechanisms including their
reaction with other cellular components, such as amino acids, lipids, or sugars,
which gives rise to various electrophiles with diverse biological activities. The
electrophiles generated can interact with chemical groups of nucleophilic char-
acter, such as the thiol groups present in cysteine residues of proteins or in the
tripeptide glutathione (GSH). The modification of cysteine residues by these
diverse species completely alters their physicochemical properties and has im-
portant functional consequences. For these reasons much attention has been
devoted in recent years to the identification and characterization of the struc-
tural and functional consequences of the modification of cysteine residues by
diverse reactive species under physiological or pathophysiological conditions.
The group of proteins involved in the regulation of cellular functions through
the modification of their cysteine residues could be termed sulfoproteome.
Methods for the detection of specific cysteine modifications by thiolation or
nitrosylation have been developed.2,3 These methods have allowed the iden-
tification of proteins which are targets for these modifications and in some
cases, the identification of novel signaling pathways. In addition to its role in
biological pathways, the modification of cysteine residues has been considered
of great importance for the design of novel antiviral and anticancer therapies.4
During the past 5 years several reports have highlighted the importance of the
modification of cysteine residues by electrophilic eicosanoids. This type of
modification has remarkable pharmacological consequences and its potential
physiological relevance is beginning to be unveiled. The available evidence
indicates that the direct modification of cysteine residues contributes to the
effects of electrophilic eicosanoids on the onset and the resolution of inflam-
mation, and it could provide connections between inflammatory situations and
increased proliferation. An understanding of these processes requires the iden-
tification and characterization of the electrophilic eicosanoid interactome.
EICOSANOIDS AND THEIR IMPORTANCE
IN INFLAMMATION
Eicosanoids are lipidic mediators derived from the essential fatty acid arachi-
donic acid that are involved in the regulation of multiple cellular processes,
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ranging from the regulation of vascular tone, to the modulation of gene ex-
pression and cell proliferation. Arachidonic acid is mainly found esterified to
membrane phospholipids. A variety of stimuli, including inflammatory agents
or tissue injury, activate phospholipases, mainly phospholipase A2, that release
arachidonic acid from membranes. Arachidonic acid can then be transformed
through enzymatic and nonenzymatic reactions into a wide variety of bio-
logically active compounds. Cyclooxygenase (COX) enzymes, catalyze the
limiting step in the synthesis of prostaglandins (PG), that is, the formation
of PGH2. This compound is then transformed by various PG synthases into
other PG with specific functions, and thromboxane A2 (reviewed in Ref. 5).
Arachidonic acid can be transformed into leukotrienes and lipoxins through
the action of lipoxygenase (LOX) enzymes.6 In addition, arachidonic acid
and its derivatives can suffer various nonenzymatic transformations, like free
radical-induced peroxidation, which gives rise to a series of compounds that
are known as isoprostanes.7 It is interesting to note that significant amounts of
PG can also be generated through nonenzymatic mechanisms.8 PG, in turn, can
suffer nonenzymatic dehydration to yield PG with cyclopentenone structure
(cyPG).9
Inflammation is a complex response characterized by multiple interactions
between soluble and cellular factors that tend to defend the organism against
traumatic, infectious, or autoimmune injury. At the site of tissue injury, a
complex array of substances can be released, including neuropeptides, intra-
cellular materials, or microbial antigens, which activate resident cells, such
as mast cells and macrophages. These cells in turn release inflammatory me-
diators (histamine, cytokines, NO, PG, etc.) that induce vasodilatation and
edema and contribute to attract neutrophils, which produce large amounts of
proteases and reactive oxygen species, and lymphocytes that contribute to ac-
tivate macrophages. During inflammation there are marked alterations in gene
expression. Proinflammatory stimuli induce the expression and activation of
proteins involved in the synthesis of inflammatory mediators. Inducible NO
synthase and COX-2 play a key role in the increased synthesis of NO and
PG during inflammation. Both types of mediators can amplify the response to
proinflammatory stimuli at the early stages of the inflammatory response.10,11
Thus, there are various self-amplifying mechanisms, which operate during the
onset of the inflammatory response and promote a controlled destruction of
tissue in order to remove the damaging agent. However, for this situation to
lead to healing, the mechanisms for tissue repair must be in place. The mecha-
nisms of resolution of inflammation are active and tightly regulated processes
that favor the safe disposal of inflammatory cells and the restoration of the
inflamed tissue to its physiological situation.12 During the resolution phase of
inflammation an important event takes place, referred to as “class switching,”
that affects the nature of the inflammatory mediators. This implies a reduction
in proinflammatory and an increase in anti-inflammatory mediators that con-
tribute to limit the amplitude of the response. In addition, several well-known
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inflammatory mediators can display dual effects, that is, they exert mainly
proinflammatory actions during the early phases of the inflammatory response
and inhibitory actions at late stages. An example of this is NO, for which we de-
scribed recently a biphasic effect on the response of mesangial cells to cytokine
stimulation.13 A dual nature has also been reported for other mediators like
tumor necrosis factor- (TNF-), interferon- (IFN- ), transforming growth
factor- (TGF-), and some eicosanoids, such as PGE2.14
Eicosanoids play a key role both in the onset and in the resolution of inflam-
mation. PG and leukotrienes display potent proinflammatory effects, including
vasodilatation, edema, fever, activation of neutrophil chemotaxis, increased
expression of adhesion molecules, etc.5 Isoprostanes and some of their deriva-
tives are considered an index of oxidative stress and lipid peroxidation.15 Some
isoprostane-derived products can contribute to oxidative damage through the
modification of amino acid residues in proteins that may result in protein
aggregation.16 In contrast, cyPG and lipoxins appear to display mostly anti-
inflammatory effects, including the inhibition of proinflammatory cytokine
synthesis and neutrophil chemotaxis and transmigration, and the induction
of neutrophil clearance through phagocytosis by monocytes-macrophages.17
Eicosanoid production plays an important role in the process of “class switch-
ing.” It has been reported that cyPG are generated in increased amounts at the
late stages of inflammation.18 In addition, lipoxins are generated through the
transcellular metabolism of arachidonic acid, that is, arachidonic acid or its
products generated by a class of cells are taken up by a different class, which
can convert them in lipoxins through the action of 12- or 15-LOX.12,17 This
represents a mechanism by which cell–cell interactions favor a transition in
the profile of the eicosanoids produced, from a proinflammatory to an anti-
inflammatory nature, and this has important implications for the resolution of
inflammation.
CYCLOPENTENONE PROSTAGLANDINS
cyPG are electrophilic eicosanoids that have elicited great interest re-
cently. Their common feature is the presence of an unsaturated carbonyl
group in the cyclopentane ring (cyclopentenone, see FIG. 1). CyPG are gen-
erated by spontaneous dehydration of other PG. Thus, PGA2 arises by de-
hydration of PGE2, while cyPG of the J series, including PGJ2 and 15-
deoxy-12,14 -PGJ2 (15d-PGJ2) arise from PGD2. It has been known for
over 20 years that cyPG exert antiviral and antiproliferative effects. How-
ever, a renewed interest in this area rose when 15d-PGJ2 was identified
as an endogenous ligand of the transcription factors of the PPAR (peroxi-
some proliferator activated receptor family),19 which play an important role
in the regulation of lipid metabolism and immune response. In fact, activa-
tion of PPAR has been reported to mediate some of the beneficial effects of
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FIGURE 1. Structure of cyPG and formation of Michael adducts with proteins. (A)
Structures of several cyPG of the A series (left) and of the J series (right). Electrophilic
carbons are marked by asterisks. (B) Schematic representation of the formation of a Michael
adduct between the electrophilic carbon in the cyclopentenone ring of 15d-PGJ2 (carbon
9) and the sulphydryl group of a protein cysteine residue.
15d-PGJ2 in experimental models of inflammation. However, it has been found
that many of the anti-inflammatory effects of cyPG can occur by mechanisms
independent from the activation of PPAR.9 These effects include the inhibition
of transcription factor NF-B and of the induction of several proinflammatory
genes, including iNOS, COX-2, or ICAM-1.20,21 Some of the effects of cyPG
could be observed in cell-free systems22 and required the presence of critical
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cysteine residues in NF-B or in IKK.23,24 For these reasons it was postulated
that these inhibitory effects could be mediated by the direct interaction of cyPG
with cysteine residues by Michael addition. In this context, our group provided
the first direct evidence of the interaction between cyPG and a protein target,
the p50 subunit of transcription factor NF-B, which we demonstrated by the
use of a biotinylated analog of 15d-PGJ2 combined with mass spectrometry
analysis.24 Several research groups have employed similar strategies to iden-
tify other targets of cyPG or of compounds with similar reactivity. Some of the
identified targets play important roles in the modulation of inflammatory and
proliferative processes. Anti-inflammatory cyPG may interact with the NF-B
activation pathway at multiple levels (FIG. 2), including the inhibition of the
activity of the proteasome,25 the modification of critical cysteines in IKK
and ,22,23 and also modification of cysteines present in the DNA binding
FIGURE 2. Schematic view of the NF-B activation pathway showing the sites of in-
teraction of several Michael receptors. The transcription factor NF-B plays a key role in the
inflammatory response. In a very schematic view, the pathway leading to NF-B activation
involves the stimulation of a complex with kinase activity (IKK), which phosphorylates the
inhibitory subunit of NF-B, IB. This triggers IB ubiquitination and degradation by the
proteasome, which promotes the nuclear accumulation of the active dimer, represented by
p65/p50, which activates the transcription of target genes. The NF-B activation pathway
has been the subject of numerous studies in search for anti-inflammatory molecules. Shown
is the site of action of several molecules that have been reported to interfere with NF-B
activation through the formation of covalent adducts with critical proteins of this pathway
by Michael addition.
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domains of the subunits of this transcription factor (p65 and p50).24,26 As a
result of these interactions, cyPG can inhibit the phosphorylation and/or the
degradation of the inhibitory subunit IB, and block the translocation or the
nuclear accumulation of the active factor. In addition, they may directly inhibit
the binding of NF-B proteins to DNA. The predominant effect would be de-
pendent on the cell type. 15d-PGJ2 can also target the cysteine residue present
in the DNA binding domain of c-Jun, and thus, inhibit the DNA binding activ-
ity of AP-1.27 In addition, some cyPG can bind to and inactivate thioredoxin
and thioredoxin reductase,28,29 which are involved in the control of cellular
redox status and play a role in maintaining the cysteines of NF-B and AP-1
in their reduced state, which is required for function. Therefore, the modifi-
cation of these redox-controlling proteins could also have consequences for
the modulation of the inflammatory response. Several electrophilic lipids, in-
cluding 15d-PGJ2 can also activate the transcription factor Nrf2, through the
modification and inhibition of the function of Keap1, a cytoplasmic protein
that acts as an inhibitor of Nrf2. Through this mechanism cyPG can induce the
expression of hemooxygenase and of antioxidant genes.30,31 Other identified
targets of cyPG include H-Ras and LKB1/STK11 (serine/threonine kinase 11),
proteins involved in the control of cellular proliferation.32,33 For these reasons,
cyPG have been proposed to participate in the interactions linking chronic
inflammation and increased cell proliferation.
cyPG: Are they Physiologically
or Pharmacologically Relevant?
The characterization of the biological effects of cyPG has evolved in parallel
with the exploration of their potential therapeutic use in various experimental
models of inflammation and tissue injury. 15d-PGJ2 has been reported to
display protective effects against renal ischemia-reperfusion injury,34 adjuvant-
induced arthritis,35 experimental autoimmune encephalomyelitis,36 restenosis
after angioplasty,37 etc. In some of these models, the beneficial effects have
been found to correlate with the inhibition of the activity of transcription
factors NF-B and AP-1, and with the ability of cyPG to covalently modify
proteins. Interestingly, animals deficient in PGD2 synthase show exacerbated
inflammation, thus pointing toward a protective role of PGD2 metabolites in
inflammation.38 However, the physiological relevance of the effects of cyPG is
not established. This is due to the fact that the concentrations of cyPG required
to elicit anti-inflammatory effects are generally higher than those measured
in vivo. This discrepancy could be due to the high reactivity of cyPG that
readily form adducts with thiol groups, making the detection of their total
levels in biological samples inaccurate. It also should be taken into account
that the protective effects of cyPG are not general. In some tissues, cyPG
can have toxic effects,39 or induce unwanted reactions, such as allergy or cell
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proliferation. For these reasons, the potential therapeutic use of cyPG requires
the identification of their targets and the assessment of their selectivity.
CYCLOPENTENONE ISOPROSTANES
In contrast to cyPG, the available information regarding the generation of iso-
prostanes in biological systems is more comprehensive. Roberts and Morrow
first reported that free radical-induced peroxidation of arachidonic acid could
lead to the nonenzymatic formation of bioactive PG F2-like compounds,
F2-isoprostanes, in vivo. Later, several compounds were identified that could
be formed by the isoprostane pathway (reviewed in Ref. 15). It is known that
isoprostane levels are greatly increased in various tissues under conditions of
oxidative stress or chronic inflammation, including Alzheimer, atheroscle-
rosis, and rheumatoid arthritis. In a way analogous to that described for
cyPG, nonenzymatic dehydration of isoprostanes generates compounds with
cyclopentenone structure, which are highly reactive and have been found in tis-
sues at near micromolar concentrations.40 A2 and J2 isoprostanes are isomers
of the corresponding cyPG. In a recent work,41 A and J series isoprostanes
have been found to mimic the effects of cyPG on the inflammatory response
in macrophages. These compounds can inhibit NF-B, induce apoptosis of
macrophages, and in the case of the J series, activate PPAR . These obser-
vations suggest that cyclopentenone isoprostanes could act as negative mod-
ulators of inflammation. In a way analogous to 15d-PGJ2, the isoprostane
15-A2-isoprostane has been reported to modify Keap1 and activate Nrf2.30
The availability of isoprostanes through chemical synthesis will grant a spur
in the research into their biological effects.
LIPIDIC MEDIATORS AND OTHER COMPOUNDS
WITH UNSATURATED CARBONYL GROUPS
There are other lipidic mediators, that can arise under situations of in-
flammation or oxidative stress, which possess unsaturated carbonyl groups
and may form covalent adducts with thiol groups. Among these compounds
are 5- and 15-eicosatetraenoid acid, 9- and 13-oxo-octadienoic acid,42 several
15-keto-PG, epoxycyclopentenone phospholipids,43,44 and neuroprostanes.39
These lipids act through various mechanisms, in some cases not completely un-
derstood. Also, the well-studied ,-unsaturated aldehydes 4-hydroxy-nonenal
and acrolein can be formed as products of lipid peroxidation and can react both
with thiol groups by Michael addition and with amine groups forming Schiff
bases. Several excellent reviews45,46 have dealt with the biological effects of
these reactive aldehydes; therefore, this subject will not be considered here in
more detail. In several studies, 4-hydroxy-nonenal has been shown to modify
protein targets common to cyPG.29,30,33 The predominance of protective or
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toxic effects of these electrophilic compounds appears to be concentration-
dependent and cell-type specific. It has been proposed that moderate levels of
oxidized lipids elicit an adaptative response to stress that protects cells from
subsequent oxidative insults, while high concentrations of electrophilic lipids
would induce apoptosis.47 In addition to endogenous compounds, many natu-
ral products, like active principles from medicinal herbs, possess unsaturated
carbonyl groups in their structure, which may show reactivity similar to that of
cyPG. For instance, parthenolide or the kaurane diterpene kamebakaurin,48,49
inhibit NF-B activation through mechanisms analogous to those of cyPG
(FIG. 2). In addition, herbimycin A and punaglandins have been reported to
inhibit NF-B through the formation of Michael adducts with critical cysteine
residues of components of the NF-B activation pathway.50–52 For these rea-
sons, certain natural or synthetic cyclopentenones are being studied in order
to assess their potential use as antiproliferative or anti-inflammatory agents.
DERIVATIVES OF cyPG AS TOOLS FOR THE STUDY
OF THE INTERACTIONS BETWEEN ELECTROPHILIC
EICOSANOIDS AND CELLULAR PROTEINS
Eicosanoids with cyclopentenone structure have been used in various ap-
proaches to understand the mechanism of action of electrophilic lipids. The
synthesis of cyPG allowed to explore the interactions of these compounds with
cellular structures and with proteins.53 The interaction of cyPG with cells was
explored in a series of important studies by Narumiya and co-workers.54–56
Using radioactively labeled cyPG, these authors showed that these compounds
could enter intact cells in significant amounts and that they could be found
both in cytosolic and nuclear compartments, with preferential accumulation in
cell nuclei, where cyPG were bound to an insoluble fraction. They found that
the retained radioactivity could be recovered by treatment with alkali and by
proteolytic digestion of the nuclear fraction, which suggested the formation
of Michael adducts between cyPG and nuclear proteins.56 In addition, these
authors showed that the extent of the accumulation was dependent on the struc-
ture of the cyPG. In the case of PGA2 both the binding to cellular structures
and the inhibitory effect of cell growth could be reversed by extensive washing.
In contrast, nuclear accumulation of 12-PGJ2 was only partially reversed by
cell washing and the growth inhibitory effect was irreversible.56 Therefore,
this constitutes one of the first evidences of a differential effect of cyPG with
diverse structure.
The use of a biotinylated analog of PGA2 provided one of the first evi-
dences of the binding of cyPG to cellular polypeptides by means of SDS-
PAGE and Western blot with streptavidin-alkaline phosphatase. This allowed
the visualization of several biotin-positive polypeptides whose labeling cor-
related with the inhibition of cellular proliferation exerted by PGA2 in K562
erythroleukemia cells.57 We used a modification of this procedure to provide
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the first identification and visualization of a protein that could be modified
through the stable binding of a biotinylated analog of 15d-PGJ2.24 Since then,
biotinylated analogs of cyPG have been used in several approaches to get in-
sight into the identity and consequences of protein modification by cyPG.
Biotinylated analogs of cyPG enter cells and form adducts with cellular pro-
teins that are resistant to electrophoresis under denaturing conditions. Recently,
15d-PGJ2 modified by incorporation of a fluorescent moiety has been used
to visualize the cellular sites of binding of this cyPG.58 It should be noted,
however, that, although modified cyPG possess the reactive cyclopentenone
moiety, their properties may not be identical to those of endogenous cyPG due
to the presence of the incorporated label. For instance, in a recent work, several
lipids containing ,-unsaturated ketone moieties have been reported to bind
to PPAR covalently. In this model, 15d-PGJ2 has been proposed to occupy
the ligand binding site in such a way that the carboxyl group of the PG es-
tablishes interactions with the PPAR backbone (formation of a hydrogen bond
with Tyr-473 in helix 12 of PPAR ), that are important for binding.42 This
may provide an explanation for the observation that 15d-PGJ2 biotinylated at
the carboxyl group did not detectably bind to PPAR in cells, as explored with
a pull-down assay, whereas it still bound to c-Jun or c-Fos.27 Taken together
these evidences suggest that the structural requirements for covalent binding
of 15d-PGJ2 to the PPAR ligand binding domain are different from those
involved in PPAR -independent actions. We recently described that the pres-
ence of the endocyclic double bond in 15d-PGJ2 was required for the efficient
binding of this cyPG to c-Jun and to various proteins present in a mesangial
cell lysate, in an in vitro assay,21 since an analog of 15d-PGJ2 lacking this
double bond, namely 9,10-dihydro-15d-PGJ2 failed to mimic the effects of
15d-PGJ2. This indicated that probably, carbon 9 of 15d-PGJ2 was involved
in Michael addition with the thiol groups of the proteins studied. However,
both 15d-PGJ2 and 9,10-dihydro-15d-PGJ2 bind to and activate PPAR with
similar potency,21 which indicates that the carbon important for the reaction
with the sulfur atom of the cysteine residue in PPAR is the carbon at position
13, as suggested also by molecular modeling.42
Use of Biotinylated Derivatives of Eicosanoids to Confirm
the Interaction of cyPG with Potential Targets
The observations described above indicate that electrophilic eicosanoids can
potentially bind to additional or different protein targets than their modified
counterparts. Therefore, care should be exercised when using these compounds
because it would be important to confirm that natural and modified eicosanoids
display the same mechanism of action for a particular target. In recent years,
a number of reports have used biotinylated analogs of cyPG to assess the
binding of these compounds to defined proteins in intact cells. This approach
has been used to confirm the binding of cyclopentenone moiety containing
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compounds to the p50 subunit of NF-B,24 the components of AP-1, c-Jun,
and c-Fos,27 the protein thioredoxin,28 thioredoxin reductase,29 Keap1,30 or H-
Ras,32 among others. In some cases, it has been confirmed that the biotinylated
cyPG mimics the biological effects of the nonmodified compound.24,30,59 In
addition, some studies infer the modification of the target cysteine residues
by the natural electrophilic lipids in vitro or in intact cells, by evidencing
a reduction in the ability of general cysteine reagents, such as biotinylated
iodoacetamide or fluorescent maleimide, to modify the electrophile-treated
proteins.21,30,42 However, it should be taken into account that treatment of
cells with cyPG may induce potent oxidative stress,60–62 and this may be the
cause for the occurrence of other modifications of cysteine residues, either
reversible, such as thiolation,63 or irreversible, like the formation of sulfox-
ides, that could result in decreased accessibility of the cysteine residues for
modification by thiol reagents. In addition, we have observed that treatment
of human leukemia cells with 15d-PGJ2 induces the formation of intermolec-
ular and intramolecular disulphide bonds (Sa´nchez-Go´mez et al., unpublished
observations). Therefore, ideally, the modification of cellular proteins by elec-
trophilic eicosanoids should be confirmed by the direct observation of adducts
by methods like mass spectrometry.
Proteomic Studies
Biotinylated analogs of cyPG have been used in several studies to visual-
ize and/or identify protein targets for the modification by cyPG (FIG. 3). We
recently observed the binding of biotinylated 15d-PGJ2 to approximately 50
target proteins in mesangial cells by 2D electrophoresis and Western blot with
FIGURE 3. Typical pattern of biotinylated 15d-PGJ2-modified proteins in rat mesan-
gial cells. Mesangial cells were incubated with 5 M biotinylated 15d-PGJ2 for 2 h. Cell
lysates were analyzed by 2D electrophoresis and either Coomassie Gold staining or Western
blot with horseradish peroxidase streptavidin and ECL.
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horseradish peroxidase-conjugated streptavidin.21 Levonen and co-workers,30
found nearly 30 proteins modified by biotinylated 15d-PGJ2 in human em-
bryonic kidney 293 cells. For these studies to be mechanistically relevant it
is important that the biotinylated analogs of electrophilic eicosanoids mimic
the biological effects of the nonmodified compounds. In a recent study we
have observed that biotinylated 15d-PGJ2 displays potent anti-inflammatory
effects and induces heat shock in mesangial cells, thus mimicking the effects
of 15d-PGJ2.59 In a previous study we showed that the ability of 15d-PGJ2 to
modify cellular proteins was required for the anti-inflammatory effects of this
PG. Therefore, we reasoned that the biotinylated compound could be a valid
tool to identify novel targets for cyPG, whose modification could play a role in
the anti-inflammatory effects of these compounds. We have recently reported
the identification of some of the modified proteins, which include proteins in-
volved in the heat shock response and in the organization of the cytoskeleton,
such as vimentin and tubulin.59 A recent study using also biotinylated 15d-
PGJ2 has identified 17 potential targets of the electrophile responsive proteome
in isolated liver mitochondria, thus suggesting that electrophilic lipid oxidation
products can target a subproteome in the mitochondria with consequences for
cytochrome c release and induction of apoptosis.64 The elucidation of the role
of these targets in the biological effects of electrophilic eicosanoids will grant
further developments in this field.
Study of the Selectivity of the Modification: Interactions with GSH
Some cyPG have shown beneficial effects in experimental models of in-
flammation and tissue injury. Therefore, an important aspect of the study of
these compounds is the assessment of their therapeutic potential, which re-
quires a deeper knowledge of their mechanism of action and the identification
of novel targets for therapeutic intervention. In this context it is important to
ascertain the selectivity of protein modification by cyPG. The studies with bi-
otinylated analogs of cyPG described above have shown that the modification
of proteins by these compounds is a selective process, which, in spite of the
broad reactivity of cyPG, does not occur randomly but affects a defined subset
of cellular proteins. These targets are different from the proteins modified by
general cysteine reagents such as biotinylated iodoacetamide.21 By using bi-
otinylated 15d-PGJ2 and PGA1 we have recently observed that these two cyPG
bind to some common targets but also to some selective targets in NIH-3T3 fi-
broblasts.65 Therefore, selectivity of protein modification by cyPG depends in
part on the structure of the PG. In addition, the selectivity of the modification
can be observed in individual proteins. Both p50 and H-Ras possess several
accessible cysteine residues, however, only one cysteine residue is modified
by 15d-PGJ2 in either protein.24,32 In H-Ras, cysteine 184, out of the six cys-
teine residues of the protein, has been found to be the main site for 15d-PGJ2
560 ANNALS NEW YORK ACADEMY OF SCIENCES
FIGURE 4. Selectivity of the modification of the cysteine residues in p50 by biotiny-
lated 15d-PGJ2 and PGA1. Wild type (wt) or cysteine 62 to serine mutant p50 (C62S) at 0.5
M was incubated with 1 M biotinylated 15d-PGJ2 or PGA1 for 1 h at r.t. Biotin incorpo-
ration was monitored by Western blot with horseradish peroxidase-conjugated streptavidin
and p50 levels were assessed by Western blot with anti-p50 antibody. The intensity of the
biotin signal, normalized by the signal given by the anti-p50 antibody, expressed in arbitrary
units, is shown in the lower panel. Results are representative of four assays.
binding. In addition, the binding of biotinylated analogs of 15d-PGJ2 and PGA1
to a p50 DNA binding domain construct containing seven cysteine residues is
dependent on the presence of cysteine 62, indicating that this is the main site
for cyPG addition (FIG. 4). Identification of the selective targets for modifica-
tion by cyPG could contribute to the elucidation of the mechanism of action
of endogenous eicosanoids, the structure of which is very diverse. Also, this
knowledge may aid in the identification of compounds that selectively target
certain proteins of therapeutic interest.
In addition to PG structural determinants, several factors could influence the
selectivity of protein modification by cyPG. These include factors related to
the structure of the protein, either through the establishment of additional in-
teractions with the eicosanoid,42 or due to steric factors. In addition, cysteines
with low pKa would be more susceptible to modification, and an acidic pH
in the vicinity of the adduct would contribute to its stability. It is interesting
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to note that interactions of cyPG with proteins can also be influenced by sol-
uble thiols.66 It has been reported that the formation of GSH-CyPG adducts
is a reversible process while cyPG addition to proteins appears to be virtually
irreversible under physiological conditions. It is well known that GSH is an
important factor in the biological effects of cyPG. Depletion of GSH has been
associated in several studies with a potentiation of the effects of cyPG.67,68 In
contrast, supplementation of cells with N-acetyl-cysteine, as a thiol-protective
agent, reduces the effects of cyPG.69 Therefore, there seems to exist an inverse
correlation between intracellular levels of GSH and the intensity of the bio-
logical effects of cyPG. This can be due to several mechanisms, including the
ability of GSH to form adducts with cyPG. This can occur both enzymatically,
through the action of glutathione-S-transferase (GST) enzymes, as well as
nonenzymatically. GSH-cyPG adducts are substrates for the multidrug trans-
porters, which play an important role in the detoxification of cyPG. We have
observed recently that agents that modulate intracellular GSH levels differen-
tially affect the intensity of the binding of biotinylated cyPG, 15d-PGJ2 and
PGA1 to cellular proteins.65 Biotinylated 15d-PGJ2 was more effective than
PGA1 at binding cellular proteins. Depletion of GSH with buthionine sul-
foximine increased protein modification. Conversely, supplementation with
N-acetyl-cysteine reduced the extent of cyPG addition. These changes were
more marked in the case of biotinylated PGA1. In addition, the modulation
of the binding of cyPG by GSH was not uniform for all polypeptides, thus
leading to alterations in the pattern of labeled proteins. These results suggest
that GSH levels may contribute not only to the intensity but also to the se-
lectivity of protein modification by biotinylated cyPG. These effects may be
related to the differential reactivity of two cyPG toward soluble thiols. The
15d-PGJ2 presents a dienone structure, while PGA1 is a single enone. Adducts
of single enone cyPG and GSH have been reported to be more stable than
dienone cyPG-GSH adducts.66 This may be the reason why GSH levels affect
the binding of biotinylated-PGA1 to proteins more intensely. However, as out-
lined above, the effect of GSH does not affect uniformly all proteins. We have
addressed this issue by exploring the effect of GSH on the incorporation of
biotinylated cyPG to several purified proteins in vitro. We have observed that
GSH reduces the modification of GST, but it can improve the modification of
p50 (Gayarre et al., unpublished observations). These opposite effects could be
due to several mechanisms. GSH or GSH conjugates can alter the conforma-
tional status of GST modifying the orientation of critical cysteine residues.70
This could preclude binding of cyPG. On the other hand, our results indicate
that GSH may favor the incorporation of cyPG into certain proteins by con-
tributing to the maintenance of critical cysteine residues in a reduced state,
and therefore, accessible for modification. Extensive protein oxidation due to
oxidative stress or GSH depletion would then lead to an inhibition of the incor-
poration of cyPG and probably to an attenuation of cyPG-specific effects. It
is interesting to consider that under situations of oxidative stress or increased
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NO generation, the GSSG or GSNO formed can act as thiolating agents and
induce reversible protein glutathiolation. In several proteins, for instance, in
c-Jun and p50, the cysteine residues that are targets for modification by cyPG
are also targets for glutathiolation. Therefore, these two types of agents, ox-
idant species derived from GSH and cyPG, may compete for binding to the
same residue(s). In fact, glutathiolation under these conditions, could act as a
defense mechanism protecting critical cysteine residues in signaling proteins
from the irreversible addition of cyPG, as it has been proposed previously in
the context of oxidative or nitrosative stress.71
The effects of GSH levels on the biological actions of electrophilic
eicosanoids could be mediated by an additional mechanism. It has been re-
cently reported that certain synthetic cysteine adducts of cyclopentenones can
display potent biological activity.72 In addition, it is well known that GSH
adducts of several endogenous oxyeicosanoids retain biological activity or can
even display novel actions.73 Therefore, the formation of cyPG-GSH adducts
could give rise to the appearance of biochemical species with effects and mech-
anisms of action different from those of the parent cyPG.
Subcellular Localization of Cellular Targets
for Electrophilic Eicosanoids
The early studies with radioactive cyPG already detected important differ-
ences in the subcellular distribution of cyPG depending on their structure, with
single enone cyPG being present as soluble species in a higher proportion than
dienone cyPG.56 The subcellular fate of cyPG has also been explored by means
of biotinylated or fluorescent analogs of cyPG. These studies have shown cell
type-dependent differences in the subcellular distribution of cyPG. In HeLa
cells incubated with biotinylated 15d-PGJ2, a predominantly nuclear stain-
ing has been observed,74 while in mesangial cells both nuclear and cytosolic
compartments show biotin staining.21 These observations may correlate with
some of the biological effects of cyPG described in both cell types. 15d-PGJ2
inhibits NF-B activation in both systems. However, the mechanism of inhi-
bition appears to involve mainly nuclear events in HeLa cells,24,26 and both
cytoplasmic and nuclear processes in macrophages26 and in mesangial cells.75
Interestingly, GSH levels and/or GST activity have been proposed to play
an important role in the predominance of either cytosolic or nuclear effects of
cyPG.26,53 It is tempting to speculate that these factors could also influence the
cellular compartment in which cyPG would preferentially bind to their targets.
A recent study using a fluorescent derivative of 15d-PGJ2 indicates that this
compound localizes significantly to the mitochondria in endothelial cells.58 It
has been proposed that interaction with mitochondrial proteins contributes to
the oxidative stress induced by this compound.58
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Induction of Protein Cross-Links
One of the mechanisms by which electrophilic lipids can damage proteins
is by inducing protein cross-links. This appears particularly relevant in the
case of electrophilic aldehydes, such as 4-hydroxy-nonenal, isoketals, and le-
vuglandins.16 The consequence of this modification can be the accumulation
of the modified proteins that cannot be degraded by the proteasome, and the
formation of anomalous aggregates that may damage cells and contribute to
the pathophysiology of several processes, including inflammatory diseases
and neurodegeneration.16 It is interesting to note that certain cyPG possess a
dienone structure, and therefore they could form Michael adducts with two cys-
teine residues. In fact, 9-deoxy-9,12(E)-PGD2, which possesses two elec-
trophilic carbons, has been described to form a conjugate with two molecules
of GSH.76 In this context, we have recently described that 15d-PGJ2, a dienone,
can induce cross-linking of the protein c-Jun,27 thus providing the first example
of protein cross-linking induced by cyPG. This effect could also be observed
in mutant c-Jun constructs which only possess one cysteine residue, like the
C320S c-Jun mutant, which only presents the cysteine residue located in the
DNA binding domain, cysteine 269 (FIG. 5). The dimer formed by treatment
with 15d-PGJ2 was resistant to electrophoresis under denaturing and reduc-
ing conditions. In contrast, treatment with H2O2 induced the dimerization of
C320S c-Jun, which was reversed by incubation with dithiothreitol (DTT). In
addition, in assays performed with biotinylated 15d-PGJ2 we could observe the
presence of biotin signal in the c-Jun dimer. Taken together, these observations
are strongly indicative of the participation of 15d-PGJ2 as the cross-linking
bridge in the oligomer. Therefore, it would be important to assess whether other
electrophilic lipids with dienone structure can induce a similar phenomenon
in c-Jun or other proteins and what could be its functional relevance.
CONCLUSIONS AND PERSPECTIVES
Electrophilic eicosanoids are gaining importance both as signaling
molecules and as potential pharmacological agents. In recent years, the work
of numerous research groups has greatly broadened our knowledge of their
generation, mechanisms of action, and pathophysiological and/or biochemical
importance. The use of prostanoids with cyclopentenone structure in diverse
experimental approaches has allowed exploring the subcellular localization,
target identity, structural implications and functional consequences of the mod-
ification of cellular proteins by electrophilic eicosanoids (FIG. 6). In spite of
this there are many aspects of the biology of these lipids that remain to be elu-
cidated and will probably be the subject of intense research in the future. Much
needs to be learned about the potential selectivity of protein modification by
eicosanoids and its importance in their biological actions. It would be also
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FIGURE 5. Involvement of 15d-PGJ2 in c-Jun cross-linking. (A) A C320S mutant
c-Jun construct was incubated the presence of 15d-PGJ2 (10 M) or H2O2 (1 mM) for
30 min at 37◦C. Incubation mixtures were treated with 50 mM iodoacetamide before of
after treatment with 10 mM DTT, as indicated, and analyzed by nonreducing SDS-PAGE
and Coomassie staining. The position of c-Jun monomer and dimer is indicated. (B) c-
Jun C320S was incubated in the absence or presence of biotinylated 15d-PGJ2, subjected
to SDS-PAGE under reducing conditions and analyzed by Western blot with horseradish
peroxidase-conjugated streptavidin to reveal biotinylated 15d-PGJ2 incorporation, and with
anti-c-Jun antibody to show the position of c-Jun monomer and dimer.
interesting to explore the potential reversibility of these modifications in some
proteins, or their effects on protein turnover. The elucidation of the physi-
ological or pathophysiological roles of some electrophilic eicosanoids, such
as cyPG, will require a detailed study of their generation in diverse situa-
tions and the use of sensitive methods for isolation and quantitation. In this
context, a significant challenge will be the detection and identification of pro-
teins modified by endogenous eicosanoids. In parallel, it would be important
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FIGURE 6. Diverse experimental approaches employed in the characterization of the
electrophilic eicosanoid-protein interactome through the use of cyPG derivatives.
to continue the assessment of the therapeutic potential of cyPG-based active
species.
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